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Key Points
• B-cell–specific expression of
Myd88p.L252P leads to the
development of DLBCL in
mice.
• The Myd88p.L252P mutation
cooperates with BCL2
amplifications in ABC-DLBCL
lymphomagenesis in vivo.
The adaptor proteinMYD88 is critical for relaying activationof Toll-like receptor signaling
to NF-kB activation. MYD88 mutations, particularly the p.L265P mutation, have been
described in numerous distinct B-cell malignancies, including diffuse large B-cell
lymphoma (DLBCL). Twenty-nine percent of activated B-cell–type DLBCL (ABC-DLBCL),
which is characterized by constitutive activation of the NF-kBpathway, carry the p.L265P
mutation. In addition, ABC-DLBCL frequently displays focal copy number gains affecting
BCL2. Here, we generated a novel mouse model in which Cre-mediated recombina-
tion, specifically in B cells, leads to the conditional expression of Myd88p.L252P (the
orthologous position of the humanMYD88p.L265P mutation) from the endogenous locus.
These mice develop a lymphoproliferative disease and occasional transformation into
clonal lymphomas. The clonal disease displays the morphologic and immunophenotyp-
ical characteristics of ABC-DLBCL. Lymphomagenesis can be accelerated by crossing in
a further novel allele, which mediates conditional overexpression of BCL2. Cross-validation experiments in human DLBCL samples
revealed that both MYD88 and CD79B mutations are substantially enriched in ABC-DLBCL compared with germinal center B-cell
DLBCL. Furthermore, analyses of human DLBCL genome sequencing data confirmed that BCL2 amplifications frequently co-
occurred with MYD88 mutations, further validating our approach. Finally, in silico experiments revealed that MYD88-mutant ABC-
DLBCL cells in particular display an actionable addiction to BCL2. Altogether, we generated a novel autochthonousmousemodel of
ABC-DLBCL that could be used as a preclinical platform for the development and validation of novel therapeutic approaches for the
treatment of ABC-DLBCL. (Blood. 2016;127(22):2732-2741)
Introduction
Toll-like receptors (TLRs) belong to a class of pattern-recognition
receptors.1 Ten distinct human TLRs have been described.1 Except
for TLR3, all TLRs require the adaptor protein MYD88 to initiate
downstream signaling.1,2 Upon TLR activation,MYD88 is recruited to
the Toll/interleukin-1 receptor (TIR) domain of the activated TLR via
its own TIR domain.3MYD88 recruits IRAK1, -2, and -4 to ultimately
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form the myddosome.4 IRAK4-mediated phosphorylation of IRAK1
and IRAK2 promotes TRAF6 recruitment,5 which subsequently
ubiquitylates and activates TAK1,6 leading to NF-kB activation.2
Inappropriate TLR signaling through somaticMYD88mutations has
been described in numerous hematologic malignancies, such as chronic
lymphocytic leukemia (CLL),7 Waldenstro¨m macroglobulinemia,8 and
diffuse largeB-cell lymphoma (DLBCL).9Specifically, 29%of activated
B-cell–type DLBCLs (ABC-DLBCLs), which typically display con-
stitutive NF-kB activation, carry the p.L265P mutation (position
according to the protein accessionNP_002459) in the hydrophobic core
of the MYD88 TIR domain.9 ABC-DLBCL was shown to display
MYD88p.L265P-dependent NF-kB activation and STAT3 phosphoryla-
tion.9 The MYD88p.L265P mutation is exceedingly rare in non-ABC-
DLBCLs, such as germinal center B-cell (GCB) and primarymediastinal
B-cell lymphoma.9 Moreover,MYD88p.L265P-mutant ABC-DLBCL ap-
pears to be dependent on continued MYD88p.L265P expression.9 To-
gether, these data implicate MYD88-dependent oncogenic NF-kB
signaling as an integral contributor to ABC-DLBCL pathogenesis
and as a potential therapeutic target. However, despite the clinical
relevance of theMYD88p.L265Pmutation, no autochthonous mouse
model that faithfullymimics this critical genomic aberration has yet
been generated.
Materials and methods
Experimental mice
B-cell–specific Cre expression was achieved by using Cd19Cre,10 AidCre,11 and
Cd21Cre12 deleter mouse strains (The Jackson Laboratory). The targeting vector
depicted in Figure 1A was constructed by using standard techniques. The gene
targeting strategy was based on the National Center for Biotechnology
Information transcript NM_010851.2 in which exon 1 contains the translation
initiation codon. Wild-type (wt) exons 2-6, including the entire 39 untranslated
region were flanked with LoxP sites. An additional polyadenylation signal
(human growth hormone polyadenylation [hGHpA] signal) has been inserted
between the39untranslated regionand thedistalLoxP site toprevent downstream
transcription of themutated exon5.The size of theLoxP-flanked region is 4.7 kb.
Exons 2-6, including the splice acceptor site of intron1, havebeenduplicated and
inserted downstream of the distal LoxP site. The p.L252P mutation has been
introduced into the duplicated exon5. Positive selectionmarkerswereflanked by
Frt (neomycin resistance;NeoR) and F3 (puromycin resistance;PuroR) sites and
inserted into intron 1 and downstreamof the hGHpA, respectively. The targeting
vectorwasgeneratedbyusingBACclones from theC57BL/6JRPCIB-731BAC
library andwas transfected into theC57BL/6NTac embryonic stem(ES) cell line.
Targeted clones were isolated by using double positive (NeoR and PuroR)
selection, and correct integration was verified by Southern blotting. Upon
blastocyst injection, germ line–transmitting transgenic mice were received.
The conditional Myd88c-p.L252P allele was obtained after in vivo Flp-mediated
removal of the selection markers. This allele expresses the wild-type Myd88
protein, because the presence of the hGHpA cassette downstream of wild-
type exon 6 prevents transcription of the mutant exons 2-6. The constitutive
Myd88p.L252P allele is obtained after in vivo Cre-mediated deletion of wild-type
exons 2-6 and hGHpA. This allele expresses the mutant Myd88L252P
protein. The remaining recombination sites are located in nonconserved
regions of the genome. To generate conditional BCL2 knockin mice
(Rosa26LSL.BCL2.IRES.GFP), a Rosa26 locus-targeting vector was used in
which CAGS (cytomegalovirus early enhancer/chicken b actin) promoter-
driven expression of the transgene (BCL2) and downstream expression
of an internal ribosomal entry site–driven green fluorescent protein
(IRES-GFP, as a reporter for Cre-mediated recombination) is prevented by
a LoxP-flanked STOP cassette (supplemental Figure 5C, available on the
Blood Web site). The transgenic mice expressed the transgenes only after
Cre-mediated excision of the LoxP-flanked STOP cassette. The targeting
vector was electroporated into ES cells (BRUCE4), which were screened
for correct integration by standard Southern blot methods. Correctly
targeted ES cells were used to generate chimeras, which were back-
crossed onto a pure C57BL/6N background and examined for germ line
transmission.
The Em:Myc model has been described earlier and was used, as previously
described.13 The Em:Tcl1 model of CLL was described earlier.14 All the
experiments that involved the breeding and/or treatment of rodents were
approved by the local animal care committee and the relevant authorities
(Landesamt fu¨r Natur, Umwelt und Verbraucherschutz Nordrhein-
Westfalen, AZ: 84-02.04.2014.A146/A083).
Transplantation experiments
Animal protocols based on the Em:Myc transgenic mouse model as used in this
studywere approvedby the local governmental reviewboard (LandesamtBerlin)
and conformed to regulatory standards. Isolation, retroviral infection,
transplantation of Em:Myc transgenic fetal liver cells (ie, hematopoietic
stem cells), and subsequent monitoring of the recipient mice regarding
lymphoma onset were performed as previously described.15 Specifically,
numerous independently isolated fetal liver cell populations were stably
transduced with a murine stem cell virus-based Myd88p.L252P-IRES-GFP
retrovirus or a murine stem cell virus–empty GFP construct as a control
before their propagation in recipient mice.
Immunohistochemistry
Formalin-fixed paraffin-embedded (FFPE) murine samples were sliced at 2 to
4 mm. Sections were stained with hematoxylin and eosin (H&E) and antibodies
againstKi-67 (CellMarque),B220 (RA3-6B2BD,), p65 (C-20;SantaCruz,), Irf4
(M-17; Santa Cruz Biotechnology,), Bcl6 (C-19; Santa Cruz Biotechnology),
and Cd138 (553712; BD). Staining intensities were scored by 2 independent
observerswho used a 4-tier scale. FFPEhuman sampleswere sliced at 2 to 4mm.
Sections were stained with H&E and antibodies against CD10 (NCL-L-CD10-
270;Novocastra), BCL6 (M7211;Dako), IRF4 (M7259;Dako), BCL2 (M0877;
Dako), and CD138 (138M-16; Cell Marque).
Sequence analysis of immunoglobulin genes and cloning of
polymerase chain reaction products
RNA was extracted from sections of frozen biopsies with TRI Reagent (Sigma,
Taufkirchen, Germany). One microgram of RNA was converted to comple-
mentary DNA with QuantiTect Reverse Transcription Kit (Qiagen, Hilden,
Germany). Mouse IgH rearrangements were analyzed by using previously
published methods.16 Each polymerase chain reaction (PCR) was analyzed on a
Qiaxcel Advanced Instrument (Qiagen) by using ScreenGel Software v1.2.
Direct sequencing was performed with the ABI Prism Dye Terminator Cycle
Sequencing Ready Reaction Kit v3.1 (Life Technologies, Darmstadt, Germany)
on an ABI 3130 sequencer (Applied Biosystems, Foster City, CA). Sequences
were analyzed by using 4Peaks Software v1.7.2 (The Netherlands Cancer
Institute, Amsterdam, The Netherlands), Lasergene software (DNAStar,
Madison, WI), and by manual review. Sequences were compared with mouse
germ line Ig gene sequences with International ImMunoGeneTics database.17 In
addition, the PCRproducts of 1 casewere clonedwith the TOPOTACloningKit
(LifeTechnologies),which resulted in32sequences.Togenerategenealogic trees,
sequence analysis focused on the IGHV segment, startingwithin FR1. To exclude
possible Taq errors, only mutations shown more than once were considered for
analysis (see supplemental Data).
Results
To assess the role of MYD88p.L265P in B-cell lymphomagenesis, we
generated a conditional Myd88p.L252P allele (Myd88c-p.L252P) that is
expressed from the endogenous locus upon Cre-mediated recombina-
tion (Figure 1A).MurineMyd88p.L252P is at the orthologous position of
human Myd88p.L265P. To verify Cre-inducible Myd88p.L252P expres-
sion, we derived murine embryonic fibroblasts (MEFs) fromwild-type
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and Myd88c-p.L252P/c-p.L252P mice. By using Sanger sequencing,
we detected expression of Myd88wt messenger RNA (mRNA) in
both Myd88wt/wt and Myd88c-p.L252P/c-p.L252P MEFs, indicating
lack of background expression of Myd88p.L252P in the absence of
Cre recombinase. In contrast, cytomegalovirus promoter-driven Cre
expressionmediated by lentiviral transduction ofMyd88c-p.L252P/c-p.L252P
MEFs induced recombination in the Myd88 locus, leading to ex-
pression of Myd88p.L252P-mutant mRNA (Figure 1B). Myd88
protein abundance was unaffected by stable Cre expression,
indicating that the Myd88p.L252P isoform is expressed at endog-
enous levels (Figure 1C). This Myd88p.L252P expression translated
into robust p65 Ser-536 phosphorylation, indicating activation of
NF-kB signaling (Figure 1D).
To determine whether B-cell–specific Myd88p.L252P expression
promotes lymphomagenesis, we compared Cd19Cre/wt;Myd88c-p.L252P/wt
(hereafter M-Cd19) and Cd19Cre/wt (hereafter Cd19) mice. The mice
were longitudinally monitored by magnetic resonance imaging
(MRI). Although no gross lymphoproliferative disease (LPD) was
detectable in Cd19 mice, M-Cd19 mice developed splenomegaly
and occasional lymphadenopathy starting at the age of;60 weeks
(Figure 2B). SimilarMRImorphologic signs of LPDwere observed
when B-cell–specificMyd88p.L252P expression was induced by Cre
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Figure 1. Construction of a conditional Myd88p.L252P allele. (A) Targeting of the Myd88 locus in C57BL/6N Tac ES cells. The endogenous Myd88 locus was targeted with
the linearized vector described in the supplemental Data. The targeted allele before (middle panel) and after Flp-mediated recombination of FRT and F3 sites (bottom panel) is
schematically depicted. The Southern blots of BauI, Eco91I, and KpnI digested genomic DNA probed with a 59, a 39, and a Neo probe, respectively, are shown below the
schematic illustration of the targeting strategy. Positions of restriction sites and probes are shown in the schematic drawing above. (B) Myd88p.L252P mRNA is expressed upon
Cre-mediated recombination in MEFs. Myd88wt/wt and Myd88c-p.L252P/c-p.L252P MEFs were isolated. RNA was isolated from both cell lines before LentiCre application (Sanger
sequencing chromatograms, top and middle panels) and the Myd88 mRNA sequence was determined after reverse transcription. The wild-type sequence was
recovered from both cell lines. After LentiCre application and puromycin selection, only the p.L252P sequence could be recovered from Myd88c-p.L252P/c-p.L252P
MEFs (Sanger sequencing chromatogram, bottom panel). (C) The Myd88p.L252P isoform is expressed in Myd88c-p.L252P/c-p.L252P MEFs after LentiCre-mediated recombination.
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polyacrylamide gel electrophoresis (SDS-PAGE) and blotted onto polyvinylidene difluoride membranes before Myd88 and b-actin, which served as loading controls, and were
visualized by immunoblotting. Both Myd88wt and Myd88p.L252P proteins were expressed at equal levels. (D) Conditional LentiCre-mediated Myd88p.L252P expression leads to
p65 Ser-536 phosphorylation.Myd88wt/wt andMyd88c-p.L252P/c-p.L252P MEFs were transduced with LentiCre and puromycin selected, as in (B). Upon selection, cells were lysed,
proteins were separated on SDS-PAGE, and pSer-536 p65 was visualized by immunoblot. SAH, short arm of homology; LAH, long arm of homology; pA, polyadenylation signal
sequence.
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Figure 2. B-cell–specific Myd88p.L252P expression drives lymphoproliferation and lymphomagenesis in vivo. (A) B-cell–specific expression of Myd88 p.L252P
significantly reduces overall survival in vivo. Kaplan-Meier curves illustrate the overall survival of M-Cd19 mice. M-Cd19 mice display a significantly reduced survival compared
with the respective controls (log-rank test). (B) Serial MRI scans in 16-, 34-, and 70-week-old M-Cd19 mice revealed the occurrence of splenomegaly in 70-week-old M-Cd19
mice. (C) M-Cd19 mice display splenomegaly at the time of death. Preterminal M-Cd19 and Cd19 mice were sacrificed and spleen weight was recorded. Bars represent the
average (n 5 3); error bars represent standard deviations. (D) M-Cd19 mice develop lymphoproliferative disease and occasional lymphoma. The top panels show H&E
staining of spleens and livers isolated from C57BL/6 and M-Cd19 mice at the time of death. Although the organ architecture appeared normal in C57BL/6 wild-type mice, the
architecture of spleens isolated from M-Cd19 mice was largely disrupted by infiltration of small mature lymphocytes (LPD columns) or large blastoid cells (DLBCL columns).
The bottom panel shows the partial and complete disruption of the spleen by infiltrates with high proliferative indices. (E) Immunohistochemical characterization of the liver
infiltrates of M-Cd19 mice. Areas of infiltrates morphologically resembling DLBCL (marked with solid triangles) showed a homogeneous staining pattern of B220 and Irf4
positivity, whereas they were negative for Bcl6 and Cd138 (bottom panel). Infiltrated areas of small, mature lymphocytes (marked with open triangles) displayed a more
heterogeneous staining pattern of positive and negative cells for B220, Irf4, and Cd138, whereas staining was largely negative for Bcl6 (middle panel). (F) The lymphoma cells
infiltrating spleens and livers of M-Cd19 mice displayed a largely nuclear localization of p65, indicating NF-kB activation. Black arrows indicate hepatocytes, black arrowheads
indicate cytoplasmic p65 staining in splenic lymphocytes in C57BL/6 wild-type mice, and white arrowheads indicate nuclear p65 staining in lymphoma cells in M-Cd19 mice.
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expression that was driven off the Aid promoter (hereafter M-Aid),
which is active in GCB cells, during both T cell–dependent and
–independent immune responses (supplemental Figure 1A).11,18
Furthermore, Cd21 promoter-driven Cre, which is expressed when
immature transitional B cells differentiate into mature long-lived
peripheral B cells,12 induced an LPD in Cd21Cre/wt;Myd88c-p.L252P/wt
mice (hereafterM-Cd21) thatwas indistinguishable from thatobserved
in M-Cd19 mice (supplemental Figure 1A).
The MRI morphologic occurrence of lymphoproliferative lesions
translated into a significantly (P 5 .0075) reduced overall survival of
M-Cd19 mice (median survival, 501 days) compared with Cd19 mice
(median survival, not reached in 10 mice observed for 427 to 581 days
[average, 539 days]) (Figure 2A). Similar datawere obtainedwhenCre
expression was driven off the Aid or Cd21 promoter in M-Aid and
M-Cd21 mice (median survival, 574 and 610 days, respectively)
(supplemental Figure 1B). We noted that the majority of M-Cd19,
M-Aid, and M-Cd21 mice included in this study displayed splenomeg-
aly (4 of 4, M-Cd19; 2 of 3, M-Aid; and 2 of 3, M-Cd21), occasionally
accompanied by macroscopic lymphadenopathy (1 of 4, M-Cd19; 2 of
3, M-Aid; and 1 of 3, M-Cd21). The strong oncogenic potential of the
Myd88p.L252Pmutation was also verified in an alternative mouse model
of aggressive B-cell lymphoma in which Myd88p.L252P dramatically
shortened tumor onset driven by oncogenic Myc (Em:Myc transgenic
fetal liver cells transplanted into lethally irradiated recipient mice, stably
transducedwith either empty vector [n5 40;median onset not reached]
orMyd88p.L252P [n5 12; median onset, 36 days]; log-rankMantel-Cox
P, .0001) (supplemental Figure 2).
To characterize the disease occurring in M-Cd19 mice, we initially
performed histologic examinations. H&E staining of spleens and livers
ofM-Cd19,M-Aid, andM-Cd21mice revealed infiltrates of lymphoid
cells in these organs. In particular, the architecture of the spleens of
thesemice was largely disrupted by these infiltrates (4 of 4, M-Cd19; 3
of 3,M-Aid; 3 of 3,M-Cd21).Of note,we did not detect any infiltration
of the bone marrow (n 5 3 per genotype; supplemental Figure 3).
Further analyses of the splenic and hepatic infiltrates revealed that these
lesions constituted a largely monomorphic lymphoid cell population
with indolent appearance, consistent with an LPD. Intriguingly, in a
subset of mice (1 of 4, M-Cd19; 1 of 3, M-Aid; and 1 of 3, M-Cd21),
diffuse large lymphoid infiltrates resembling DLBCL were detectable
(Figure 2D; supplemental Figure 1D-E). Of note, the Ki-67 indices
did not substantially differ between areas with LPD and DLBCL
morphology (Figure 2D). To determine the clonality of these infiltrates,
we next performed Southern blot analyses to detect clonal immuno-
globulin (Ig) rearrangements. We were not able to detect clonal Ig
rearrangements in genomic DNA isolated from areas with LPD-like
appearance that were detected in M-Cd19, M-Aid, and M-Cd21 mice
(supplemental Figure 4A). Strikingly, oligoclonal Ig rearrangement
patterns were detected in DNA isolated from infiltrates that displayed
DLBCL-like morphology in M-Cd19, M-Aid, and M-Cd21 mice
(indicated bywhite triangles in supplemental Figure 4A).DNA isolated
fromspleensof anEm:Tcl1-drivenCLLmousemodel servedasapositive
control for the development of a clonal lymphoid neoplasm.14Altogether,
our data strongly indicate that B-cell–specificMyd88c-p.L252P expression
largely leads to an LPD, with only occasional development of
mono-/oligoclonal lymphoma.
To further characterize the LPD and lymphomas, we next per-
formed immunohistochemistry in liver infiltrates of M-Cd19 mice. As
shown inFigure 2E, the areaswithDLBCL-likemorphology displayed
a strikingly uniform staining pattern. These lesions were B220 and
Irf4 positive and were Bcl6 and Cd138 negative, resembling the
immunophenotype of a post-GCB lymphoidmalignancy.19 In contrast,
the areas of LPD displayed a rather heterogeneous staining pattern for
B220, Irf4, and Cd138 and were largely negative for Bcl6, further
underscoring the nonclonal characteristics of these lesions. We noted
that areas of LPD and DLBCL-like morphology in M-Aid and
M-Cd21 mice displayed similar staining patterns (supplemental
Figure 1F-G).
To further interrogate thenature of theDLBCL-like lesions,wenext
used immunohistochemistry to assess subcellular NF-kB localization,
because constitutive NF-kB activation, indicated by nuclear enrich-
ment, is a hallmark feature of ABC-DLBCL.9 These experiments
revealed a uniform nuclear staining of the NF-kB subunit p65 in the
DLBCL-like lesions detected in spleens and livers of M-Cd19,M-Aid,
and M-Cd21 mice (Figure 2F; supplemental Figure 1C). Given that
ABC-DLBCL, which is characterized by constitutive NF-kB activa-
tion, carries the p.L265P mutation in 29% of the cases,9 and given that
the clonal lymphoproliferationwe observed inM-Cd19mice displayed
morphologic features of DLBCL, we hypothesized that the B-cell–
specificMyd88c-p.L252P expression drives ABC-DLBCL development in
our model.
To cross-validate our observations, we analyzedMYD88 mutation
frequency in human DLBCLs (n5 24, GCB-DLBCL; n5 21, ABC-
DLBCL).We performed targeted sequencing of FFPE-extracted DNA
bymultiplex PCR covering theMYD88, ATM, BTK,CD79B,DDX3X,
FBXW7, MAPK1, NOTCH1, PIK3CA, PIK3CD, PTEN, PTPN6,
SF3B1, TP53, and XPO1 genes (Figure 3A). DLBCL subtypes were
determined based on immunohistochemical stains for CD10, BCL6,
and IRF4 following the Hans algorithm (Figure 3B).19 The non-GCB
of Hans algorithm was designated as “ABC” in our study. Confirming
previously published data, we found a substantial overrepresentation
of MYD88 and CD79B mutations in ABC-DLBCLs compared with
GCB-DLBCLs (Figure 3A,C; supplemental Table 1).9,20,21 Further-
more, the anti-apoptotic oncogene BCL2 is frequently deregulated
in human DLBCL.22,23 Whereas the chromosomal translocation
t(14;18)(q32;q21), which juxtaposes BCL2 and the IGHV enhancer,
is commonly observed inGCB-DLBCL,23 focal copynumber gains are
more commonly observed in ABC-DLBCL (;30% to 40%).22-25
Indeed, mining of the whole-genome sequencing data on DLBCL
from the German International Cancer GenomeConsortiumMolecular
Mechanisms in Malignant Lymphoma by Sequencing Project (https://
icgc.org/ and C.L., M.S., and R.S., manuscript in preparation) revealed
that 6 DLBCLs carry the MYD88p.L265P mutation. Remarkably, all of
these samples belonged to theABC-DLBCL subtype and carried a copy
number gain of 18q detected by both fluorescent in situ hybridiza-
tion with a BCL2-specific probe and somatic copy number variant
mapping.26,27 A critical role for BCL2, particularly in activated B cells,
is further corroborated by published transcriptome analyses. Specifi-
cally,BCL2mRNAwasnot expressed inGCBcells butwasmassively
induced during activation of peripheral blood B cells.28 Consistent
with this, the majority of ABC-DLBCLs displayed BCL2 mRNA
levels more than fourfold higher than GCB cells.28 Furthermore,
exogenous expression of MYD88p.L265P in B cells was recently
shown to induce the accumulation of self-reactiveB cells in vivo only
when apoptosis was opposed by Bcl2 overexpression.29 Additional
circumstantial evidence suggesting that ABC-DLBCL in particular
might depend on functional BCL2 activity could be derived from
recently published, large-scale in vitro drug sensitivity profiling
experiments. Specifically, re-assessment of a data set published by
Stegmeier and colleagues revealed thatMYD88-mutant DLBCLs in
particular display an actionable BCL2 addiction, which could be
exploited by the targeted high-affinity BCL2 inhibitor ABT-263
(supplemental Figure 5A-B).30 The BTK inhibitor ibrutinib was
recently shown to synergistically interact with the BCL2 family
inhibitor navitoclax (ABT-263) in killing ABC-DLBCL cells.31 We
2736 KNITTEL et al BLOOD, 2 JUNE 2016 x VOLUME 127, NUMBER 22
For personal use only.on June 6, 2016. by guest  www.bloodjournal.orgFrom 
validated these observations in our cohort of DLBCL samples by
using immunohistochemistry to assess BCL2 expression. As shown
in Figure 3D-E, high-level BCL2 expression was significantly
enriched in ABC-DLBCL patients compared with patients who had
GCB-DLBCL. Altogether, these genomic, transcriptomic, immu-
nohistochemical, and functional data strongly suggest that enhanced
BCL2 activity plays a central pathomechanistic role in the development
of ABC-DLBCL. On the basis of these considerations, we next asked
whether lymphoma development inM-Cd19mice could be accelerated
by increased BCL2 gene dosage in vivo. To mimic BCL2 amplification
in vivo, we generated a novel conditional allele in which BCL2.IRES.
GFP was targeted into the Rosa26 locus. BCL2 expression was pre-
vented by the insertion of a LoxP.STOP.LoxP cassette upstream of the
translation-initiating codon (supplemental Figure 5C). By using this
allele,wegeneratedCd19Cre/wt;Rosa26LSL.BCL2.IRES.GFP/wt;Myd88c-p.L252P/wt
mice (hereafter M-B-Cd19), in which Cd19-driven Cre mediates the
excision of the LoxP.STOP.LoxP cassette from the Rosa26 locus,
leading to CAGS-promoter-driven BCL2 overexpression in addition
to Myd88p.L252P expression. MRI scans revealed that M-B-Cd19 mice
developed splenomegaly substantially earlier than M-Cd19, M-Aid, or
M-Cd21 mice (Figures 2B and 4B; supplemental Figure 1A). Further-
more, M-B-Cd19 mice displayed a significantly reduced overall
survival (median survival, 179 days) compared with M-Cd19,
M-Aid, and M-Cd21 mice (long-rank P 5 .0008, P5 .0001, and
P , .0001, respectively) (Figure 4A). Of note, all of the M-B-Cd19
mice displayed excessive lymphadenopathy and/or splenomegaly
at the time of death (splenomegaly in 7 of 8mice; lymphadenopathy
in 6 of 8 mice).
To further characterize the nature of the lymphadenopathy that
we observed in M-B-Cd19 mice by MRI, we next performed
histologic examination of infiltrated organs (livers, lymph nodes,
and spleens). Morphologic assessment of the splenic, hepatic, and
lymph node lesions detected in M-B-Cd19 mice revealed that
these infiltrates consisted almost entirely of diffuse large lymphoid
cells with blastoid to plasmablastoid appearance (Figure 4C).
Intriguingly, plasmablasts have been implicated as the cell of origin
of ABC-DLBCL.24 In marked contrast to the phenotype observed
in M-Cd19 mice, in which the bulk of the lesions consisted of
LPD-like infiltrates (Figure 2D), areas of LPD were only rarely
detectable in M-B-Cd19 mice. Furthermore, the Ki-67 index of the
lymphoid lesions in M-B-Cd19 mice was significantly higher
compared with lesions that emerged in M-Cd19 mice (median,
71.57%6 3.65% inM-B-Cd19 mice vs 28.27%6 2.40% in M-Cd19
mice) (Figure 4F). The Ki-67 indices observed in M-B-Cd19 mice
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matched those typically detected in aggressive human lymphoma.32
Leukemic effusion was detectable only in M-B-Cd19 mice (supple-
mental Figure 6).
Consistent with the monomorphic appearance of the blastoid
lesions detected in M-B-Cd19 mice, clonality analyses using Southern
blot to detect Ig rearrangements revealed that these infiltrates were of
clonal or oligoclonal origin (3 of 3 lesions isolated from independent
mice) (Figure 4D). Expression of the mutant Myd88 allele in the
lymphomas was verified by reverse transcriptase PCR sequencing
analysis (supplemental Figure 7). To ask whether the oligoclonal
lymphomas underwent somatic hypermutation, as would be expected
in the case of ABC-DLBCL, we analyzed a clonal lesion for Igh
rearrangements by direct sequencing. As shown in Figure 4E,we could
detect a clonal Ighv1-26, Ighd2-12, Ighj4 rearrangement. The sequence
shows an in-frame rearrangement with mutations but no stop-codons.
Thus, this rearrangement is potentially functional. Next, we cloned the
amplified Ighvgene rearrangements from this sample and sequenced32
subclones to investigate intraclonal diversity. All analyzed sequences
shared 5 mutations compared with the most homologous germ line
sequence (Ighv1-26). Further mutations could be detected in several
subclones (Figure 4E), demonstrating intraclonal diversity for this
analyzed case.
Next, we used immunohistochemistry to further character-
ize the lymphomas isolated from M-B-Cd19 mice. As shown in
Figure 4G and supplemental Figure 8, the lesions stained uni-
formly positive for Irf4 and were entirely negative for Bcl6,
consistent with the somatic hypermutation detected in Figure 4E
and further corroborating the post-germinal center (GC) nature of
the infiltrates.24 Furthermore, the lymphomas lost B220 expres-
sion and stained strongly positive for Cd138, indicating ABC
origin of these lesions.33-36 This is in line with analyses of human
DLBCL, which indicate that GC-experienced Cd138-positive
non-GC-DLBCLs are typically of plasmablastoid differentiation.37-39
In agreement with constitutive NF-kB activation, which is typi-
cally observed in human ABC-DLBCL, we found almost exclu-
sive nuclear p65 staining in the lymphomas detected in M-B-Cd19
mice (Figure 4H).
Although MYD88 mutations have not been detected in human
multiplemyeloma,8,40-42 the strongCd138 positivity of the lymphomas
growing inM-B-Cd19mice suggested the possibility that these lesions
might be of plasmacellular origin.8,40-42 However, despite considerable
effort, we were unable to detect a plasma cell expansion in the bone
marrow of M-Cd19, M-Aid, M-Cd21, and M-B-Cd19 mice. More
importantly, we did not find lymphoma infiltration of the bone marrow
inM-Cd19,M-Aid, andM-Cd21mice, andonly1of 4M-B-Cd19mice
showed an isolated lymphoma infiltrate that did not display signs
of plasmacellular differentiation (supplemental Figures 3 and 9). In
line with a lack of a consistent bone marrow infiltration, which is
an obligatory feature of Waldenstro¨m macroglobulinemia and is
frequently observed in multiple myeloma, we did not detect mono-
or oligoclonal gammopathy in either M-Cd19 or M-B-Cd19 mice
(supplemental Figure 10). However, we did detect an increased
abundance of the Ig fraction in M-Cd19 mice compared with wild-
type controls by using serum electrophoresis (upper and middle
panels of supplemental Figure 10). This gammopathy was even
more prominent in M-B-Cd19 mice (lower panel of supplemen-
tal Figure 10). The overall polyclonality strongly suggests a non-
neoplastic origin of the gammopathy observed in M-Cd19 and
M-B-Cd19 mice. Thus in summary, the morphologic appear-
ance, as well as the immunophenotype of the lesions observed in
M-B-Cd19mice strongly suggests that these lymphomas represent
ABC-DLBCL.
Discussion
Here, we generated a novel conditionalMyd88p.L252P allele, which is at
the orthologous position of the human Myd88p.L265P mutation and is
expressed from the endogenous locus upon Cre-mediated recombina-
tion. We chose to design an allele that allows expression outside the
natural genomic context tomost faithfullymimic the situation in human
malignancies. B cell–specific expression of thismutant leads to anLPD
and occasional (;30%) transformation into an aggressive lymphoma
that morphologically and immunophenotypically resembles human
ABC-DLBCL. Interestingly, development of LPD and lymphoma
occurred at a similar rate, regardless of the Cre allele. We specifically
used a pan B-cell Cre allele (Cd19Cre), a Cre allele that is active in
GCB cells (AidCre), and a Cre allele that is expressed when immature
transitional B cells differentiate into mature peripheral B cells
(Cd21Cre). These data might indicate thatMyd88p.L252P expression
leads to a block in B-cell differentiation after the GC reaction.
Consistent with this postgerminal nature of Myd88p.L252P-expressing
cells, we find that the resulting lymphomas are consistently Bcl6
negative and express Irf4 (Figure 2E; supplemental Figure 1F-G).
These observations are in line with data from human lymphoma
patients, which suggests that oncogenicMYD88mutations are enriched
in post-GC malignancies, such as ABC-DLBCL, Waldenstro¨m mac-
roglobulinemia, and the IGHV-mutant GC-experienced subset of CLL
patients.7-9,24,43-45 Furthermore, crossing in an additional allele that
allows conditional BCL2 expression from the Rosa26 locus leads to
100%-penetrant development of ABC-DLBCL.
BothMYD8846-48 and BCL224,49-51 have been shown to be critical
for transition through the GC. Thus, it is conceivable that mice
displaying B-cell–specific Myd88p.L252P expression (M-Cd19) or
Myd88p.L252P expression in combination with BCL2 overexpres-
sion (M-B-Cd19) might accumulate post-GCB cells. Consistent
with this, we find a polyclonal gammopathy in both M-Cd19 and
M-B-Cd19 mice (supplemental Figure 10).
MYD88 is frequently mutated in ;29% of ABC-DLBCL cases.9
However,MYD88mutations are even more common in Waldenstro¨m
macroglobulinemia, inwhich these alterations are detected in;90%of
the cases.8,52 Thus, it is somewhat surprising that our Myd88p.L252P-
expressing mice develop clonal ABC-DLBCL rather than Waldenstro¨m
macroglobulinemia. One possible explanation might be the different
genomic landscapes of these distinct B-cell neoplasias. For instance,
mutations in the carboxyl terminal domain of the chemokine receptor
CXCR4 have been detected in a substantial portion of patients with
Waldenstro¨m macroglobulinemia (;30% of the patients), whereas they
are absent in ABC-DLBCL.2,9,53 Furthermore, somatic mutations
affectingCD79A andCD79B are present in;20% of human ABC-
DLBCLs, whereas these alterations are rare or absent in other
lymphoma entities.20,24 Thus, it will be interesting to combine our
novel Myd88p.L252P allele with additional B-cell–specific genetic
alterations to determine whether further manipulationmight enable
a plasmacytoid differentiation.
Our novel models represent a preclinical platform that could be
exploited for the invivodevelopment andvalidationofnovel therapeutic
approaches to treat ABC-DLBCL, which remains a difficult-to-treat
clinical entity.54,55 For instance, it will be interesting to see whether
combined targeting of the apoptotic machinery and the myddosome,
through BCL2 inhibition and IRAK4 repression, will result in
synergistic toxicity inMyd88-driven ABC-DLBCL.55 Our models
might also serve to delineate the potential role of NF-kB andMAPKK6
signaling as actionable pathways downstream of the myddosome
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complex in ABC-DLBCL.56 For this purpose, it will be interesting to
assess the cytotoxic potential of TAK1, IkB kinase, and MAPKK6
inhibitors in ourMyd88-driven models of ABC-DLBCL. Altogether,
we demonstrated the oncogenic role of a novelMyd88p.L252P allele in
B-cell neoplastic disease in vivo. The resulting autochthonous mouse
models of ABC-DLBCL represent useful preclinical tools for the
development, validation, and refinement of novel treatment strategies for
ABC-DLBCL in the clinical arena.
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Supplemental Text 
 
Supplemental Materials and Methods 
 
Immunoblot  
Cells were lysed (Cell Signaling lysis buffer supplemented with phosphatase 
inhibitor cocktail [Calbiochem]) and equivalent amounts of protein (60 μg in 
Laemmli buffer) were separated on 12.5% SDS-PAGE and blotted on PVDF 
membranes (Immobilon-P, Millipore, 0.45 μm). Membranes were stained with 
specific antibodies against MYD88 (Cell Signaling, D80F5) and β-actin 
(Sigma, A2228). Proteins were detected using the ECL Western Blotting 
Detection Kit (GE Healthcare). 
?
Southern blot 
Proper genomic integration of the Myd88-targeting vector was monitored 
using Southern blot analysis from BauI genomic DNA-digests to monitor the 5’ 
integration event using a ~300 bp fragment from the genomic sequence 
upstream of exon 1 that lies outside the targeting construct as the 5' probe  
(Fig. 1A). The probe was generated by PCR amplification followed by 
radiolabeling with 32P-α-CTP using random priming. In the wildtype genomic 
Myd88 sequence, the BauI digest gives rise to an 8.8 kb band, while correct 5’ 
integration of the targeted allele gives rise to a 6 kb band due to the presence 
of a BauI site within the NeoR cassette (Fig. 1A). The 3’ integration event was 
monitored by Southern blotting using a ~300 bp probe corresponding to the 3’ 
flanking region outside the targeting construct (3' probe)(Fig. 1A). The 
targeted allele gives rise to a 13.3 kb band, while the wildtype band runs at 
11.2 kb (Fig. 1A). Single integration of the targeting vector was verified using 
a probe that hybridizes with the NeoR sequence (neo probe) on a KpnI 
genomic digest. The correct targeting event gives rise to a 6.8 kb band. No 
other bands were visible on the Southern blot, indicating a unique integration 
event (Fig. 1A). 
Correct integration of the Rosa26-targeting vector was monitored using 
Southern blot analysis from EcoRI genomic DNA-digests to monitor the 5’ 
integration event using a ~300 bp fragment from the genomic sequence 
upstream of exon 1 as the 5' probe  (Fig. S5C, S5D). The probe was 
generated by PCR amplification followed by radiolabeling with 32P-α-CTP 
using random priming. In the wildtype genomic Rosa26 sequence, the EcoRI 
digest gives rise to a 16 kb band, while correct 5’ integration of the targeted 
allele gives rise to a 7.1 kb band due to the presence of an EcoRI site within 
the NeoR cassette (Fig. S5C). Single integration of the targeting vector was 
verified using the neo probe on an EcoRI genomic digest. The correct 
targeting event gives rise to a 7.1 kb band. No other bands were visible on the 
Southern blot, indicating a unique integration event (Fig. S5D). For Southern 
blot analysis of VDJ-rearrangement, genomic DNA derived from primary and 
secondary lymphoid tissues was digested with EcoRI and transferred to a 
Hybond membrane after gel electrophoresis. The 250 bp probe JH4, derived 
from the VDJ plasmid via HindIII/NaeI digestions, was labeled with 32P-α-CTP 
and results in a 6.2 kb band for germinal center configuration, while VDJ-
rearranged alleles give bands of different sizes (see Fig. S4B). 
 
MR imaging 
MR imaging was performed on a clinical 3.0T MRI system (Ingenia, Philips, 
the Netherlands) using a small rodent solenoid coil with a diameter of 40 mm 
and an implemented heating system to keep body temperature constant 
during MRI examination (Philips Research Europe, Hamburg, Germany). 
Animals were anesthetized by a 1.5 - 2.5% isoflurane inhalation. In order to 
depict anatomic details, high resolution transversal and coronal T2-weighted 
MR images of the abdomen were acquired with the following parameters: 
turbo spin echo (TSE) factor: 10, repetition time (TR): 2674 ms, echo time 
(TE): 65 ms, flip angle: 90°, slice thickness: 1.0 mm (without gap), voxel size 
(reconstructed): 0.16 x 0.16 x 1.0 mm, matrix: 256 x 256, field of view (FOV): 
40 x 40 mm, and number of acquisition (NSA): 6, resulting in an acquisition 
time of 8:30 min for 25 slices. MR images were exported in DICOM format 
and analyzed using the research workstation Imalytics (Philips Innovative 
Technologies, Aachen, Germany). Semi-automatic segmentation of the 
spleen was performed and the volume of the spleen determined.  
 
Tumor macrodissection and DNA extraction 
Macrodissection of the tumor area was performed on six 10 µm sections of 
formalin-fixed and paraffin-embedded (FFPE) tissues. DNA was then 
automatically extracted from the tumor areas using the Maxwell platform and 
Maxwell DNA FFPE isolation kit (Promega GmbH, Mannheim Germany) 
according to the manufacturer´s instructions.  
 
?
NGS Library Construction by Multiplex PCR and deep sequencing 
Targeted deep sequencing of FFPE extracted DNA was performed by a 
multiplex PCR covering the ATM, BTK, CD79B, DDX3X, FBXW7, MAPK1, 
MYD88, NOTCH1, PIK3CA, PIK3CD, PTEN, PTPN6, SF3B1, TP53 and 
XPO1 genes. First, DNA quality and quantity from FFPE lymphoma samples 
was assessed by qPCR as described previously 16,17. 10 ng of amplifiable 
DNA was applied to multiplex PCR using the GeneRead DNAseq Panel PCR 
Kit V2 (Qiagen Inc, Hilden GER) with primer sets that were previously 
established 16. Amplicon purification was carried out by means of Agencourt® 
AMPure® XP magnetic beads (Beckman Coulter, Inc., Brea, CA, USA) on the 
robotic Biomek® FXP workstation (Beckman Coulter, Inc.). For further steps of 
library construction, the GeneRead DNA Library I Core Kit  (Qiagen) was 
applied. PCR enriched DNA was adenylated and ligated to NEXTflex™ DNA 
barcodes (Bio Scientific, Austin, Texas, USA). After Agentcourt Ampure 
purification and size selection, barcoded DNA was further enriched by 10 
PCR cycles using the NEXTflex™ primer mix (Bioo Scientific). The quality of 
amplicon libraries was evaluated by capillary electrophoresis using the 
QIAxcel Advanced System (Qiagen Inc) and 15 pM of the constructed library 
pools were finally applied to the MiSeq  (Illumina, Inc., San Diego, Ca, USA) 
using the v2 chemistry as recommended by the manufacturer. Fastq files 
were generated by the MiSeq Reporter Software (Illumina, Inc.) and analyzed 
by the CLC Genomics Workbench program (Qiagen Inc). The experiments 
involving primary human material have been approved by the internal review 
board in the framework of the BioMaSOTA (Biologische Material Sammlung 
zur Optimierung Therapeutischer Ansätze) program. 
 
Supplemental Figure 1 - Activation of Myd88p.L252P by Aid-Cre or Cd21-Cre drives 
lympho-proliferation and lymphomagenesis, in vivo. 
(A) MR imaging at the indicated times revealed the occurrence of splenomegaly in M-
Aid and M-Cd21 mice (S,  spleen; K, kidney). 
(B) B cell-specific expression of Myd88p.L252P substantially reduces overall survival, in 
vivo. The overall survival of Aid, M-Aid, Cd21 and M-Cd21 mice is illustrated in Kaplan 
Meier format. M-Aid and M-Cd21 mice display a significantly reduced survival, 
compared to the respective controls. 
(C) The infiltrates in M-Aid and M-Cd21 mice display nuclear p65 staining, indicating 
NF-κB activation. 
(D) and (E). M-Aid and M-Cd21 mice develop lympho-proliferative disease and 
occasional lymphoma, resulting in a disruption of the splenic architecture. 
Representative H/E stainings of spleens of M-Aid and M-Cd21 animals are shown. 
Asterisks mark areas of infiltrates consisting of a homogeneous large cell population 
with blastoid appearance. These areas are also displayed in a higher magnification in 
the insets (bottom right).  
In (F) and (G), the immunophenotypes of M-Aid and M-Cd21 animals are shown. 
Cells in areas of homogeneous, blastoid infiltrates are B220- and Irf4-positive, but 
stain negative for Cd138 and Bcl6. 
  
 
Supplemental Figure 2 – Myd88p.L252P expression accelerates onset of Eµ:Myc-
driven B cell lymphomas. 
A) The percentage of lethally irradiated mice with palpable lymphadenopathy at day 
100 post transplantation with Eµ:Myc transgenic fetal liver cells stably transduced with 
either empty vector, or Myd88p.L252P is shown.  
B) H/E stainings of overt lymphomas manifested in lethally-irradiated recipient mice 
that were transplanted with Eµ:Myc transgenic fetal liver cells stably transduced with 
either empty vector, or Myd88p.L252P. 
 
 
?
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Supplemental Figure 3 – M-Cd19, M-Cd21 and M-Aid mice do not display bone 
marrow infiltration. 
Histological examination of the bone marrow (n = 3 per genotype) did not reveal any 
signs of infiltration of the bone marrow by a lymphoid or lympho-blastoid population. 
 
?
?
Supplemental Figure 4 - A subset of M-Cd19, M-Aid and M-Cd21 shows clonal 
populations in VDJ-rearrangement analysis by Southern blot. 
(A) Clonal VDJ rearrangement of M-Cd19, M-Aid and M-Cd21 animals was analyzed. 
The germline configuration is present also in the WT controls and depicted as 'G'. 
Asterisks indicate clonal rearrangements. Samples of animals with lymphoma 
detected by histological analyses are marked with a white triangle (top). (B) 
Schematic illustration of the southern blot strategy. The radioactively labeled probe 
hybridizes within the J4 region. The size of the labeled EcoRI fragment depends on 
the selectd V-, D- and J segments. 
  
?
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Supplemental Figure 5 - MYD88-mutant human DLBCL cell lines display 
sensitivity towards BCL-2/BCL-XL-inhibition and construction of a conditional 
Rosa26LSL.BCL2.IRES.GFP allele.?
Pharmacological profiling revealed that MYD88-mutant DLBCL cell lines show 
significantly increased sensitivity towards ABT-263-mediated BCL2/BCL-XL inhibition, 
compared with MYD88 wildtype DLBCL cell lines. Sensitivity data derived from 19 
were assessed by half-maximum inhibitory concentration IC50 (A)?and relative growth 
normalized to DMSO (B). Significance was tested using Mann-Whitney U test. * 
indicates p < 0.05.  
(C) Targeting of the Rosa26 locus in C57BL/6N BRUCE4 ES cells. The endogenous 
Rosa26 locus was targeted with the linearized vector described in the Materials and 
Methods section. The Rosa26 allele before (top panel) and following homology-
directed gene targeting (middle panel) is schematically depicted. The Southern blots 
of EcoRI-digested genomic DNA probed with a 5' and a Neo probe, respectively, are 
shown in (D). Positions of restriction sites and probes are shown in (C). SAH, short 
arm of homology; LAH, long arm of homology. 
? ?
?
?
Supplemental Figure 6 – M-B-Cd19 mice develop leukemic effusion. 
Representative blood smears of C57BL/6 wildtype, M-Cd19 and M-B-Cd19 mice at 
the time of death are shown. While normal lymphocytes are detectable in C57BL/6 
wildtype mice (left panel), the majority of lymphocytes in M-Cd19 blood smears 
appeared to be activated (middle panel). Morphological analysis of blood smears from 
M-B-Cd19 mice revealed the presence of lymphoma cells in the peripheral blood 
(right panel). 
 
 
  
 ?
?
Supplemental Figure 7 - Lymphomas from M-B-Cd19 animals express 
Myd88p.L252P. 
RNA was extracted from fresh-frozen tumors isolated from M-B-Cd19 animals, 
reverse-transcribed and sequenced. Mutant cDNA was only detected in tumors, but 
not in wildtype control. 
 
 
?
?
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Supplemental Figure 8 - Immunohistochemical stainings of M-B-Cd19 tumors. 
Livers (A) and spleens (B) of M-B-Cd19 mice were infiltrated with a homogeneous cell 
population that with a B220- Bcl6- Cd138+ Irf4+ staining pattern with a high Ki67 index. 
 
 
?
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Supplemental Figure 9 - Bone marrow involvement is a rare event in M-B-Cd19 
animals. 
Histological examination of the bone marrow of 4 distinct M-B-Cd19 mice revealed 
locally restricted lymphoma infiltrate in one animal. 
  
  
?
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Supplemental Figure 10 - Polyclonal gammopathy in M-B-Cd19 mice. 
Serum of Cd19, M-Cd19 and M-B-Cd19 mice of different ages was analyzed by 
serum protein gel electrophoresis. M-B-Cd19 animals develop polyclonal 
gammopathy. Polyclonal gammopathy was also observed in M-Cd19 animals, albeit 
with lower frequency and to a more moderate degree. Asterisks mark contaminating 
haemoglobin bands, a technical artifact of serum preparation. 
?
sample name gene AA mutation frequency forward/reverse balance
2 ATM I1407T 14.82 0.50
4 NOTCH1 P1377S 46.98 0.49
5 NOTCH1 P1386S 6.24 0.08
5 ATM Y2019C 13.79 0.50
5 CD79B Y196C 31.56 0.26
5 NOTCH1 V726I 46.77 0.50
5 MYD88 S251N 54.10 0.50
5 NOTCH1 P1377S 55.69 0.49
6 ATM Y2019C 14.29 0.50
7 TP53 E258K 43.25 0.47
7 NOTCH1 R1279H 47.66 0.47
9 FBXW7 D440N 6.45 0.50
10 CD79B Y196H 31.15 0.23
11 DDX3X R528C 5.88 0.50
12 ATM Y2019C 10.00 0.50
14 MYD88 L265P 37.17 0.50
17 PTEN C105F 5.13 0.50
17 TP53 Q317* 7.41 0.50
17 TP53 Q331* 7.50 0.50
17 TP53 Y327* 7.55 0.50
19 ATM Y2019C 18.18 0.50
21 TP53 A161D 8.02 0.49
21 NOTCH1 Q2406* 12.98 0.49
21 ATM I1407T 14.51 0.49
21 TP53 I255S 49.94 0.49
22 PTEN L112V 6.00 0.40
22 PTEN I101T 6.25 0.40
22 PTEN C105F 6.52 0.40
22 CD79B Y196H 32.88 0.25
23 PTEN H93Q 7.08 0.14
24 ATM Y2019C 6.06 0.50
24 TP53 M246I 53.09 0.50
26 MYD88 L265P 13.22 0.50
26 CD79B Y196F 35.09 0.25
27 TP53 R213* 29.71 0.50
28 MYD88 L265P 29.39 0.50
28 CD79B Y196S 38.68 0.21
29 SF3B1 L25P 8.57 0.50
29 TP53 A86fs 90.07 0.50
31 ATM P884S 7.52 0.50
32 TP53 R248Q 45.50 0.50
32 CD79B Y196C 94.75 0.20
34 MYD88 S219C 5.00 0.50
34 ATM Y2019C 7.14 0.50
35 MYD88 S251N 38.30 0.49
36 CD79B Y196C 77.27 0.14
38 ATM Q2522H 50.00 0.26
39 ATM Y2019C 8.70 0.50
39 NOTCH1 R1279H 22.80 0.48
39 MYD88 L265P 32.74 0.50
39 CD79B Y196N 38.98 0.22
41 DDX3X T532M 28.29 0.50
41 MYD88 S219C 33.04 0.50
42 ATM Y2019C 10.00 0.50
43 TP53 D207G 24.53 0.49
43 TP53 V123G 45.06 0.49
45 MYD88 L265P 55.70 0.50
47 TP53 R282W 49.58 0.49
Knittel et al., Supplementary Table 1
47 CD79B Y196C 68.06 0.26
48 TP53 L45P 15.38 0.50
48 TP53 Q38* 15.38 0.50
48 TP53 E258K 49.49 0.47
49 ATM R2443* 5.56 0.33
49 CD79B Y196H 26.38 0.26
50 MYD88 D148Y 17.12 0.50
50 NOTCH1 P2227L 49.07 0.48
50 ATM P1054R 54.22 0.09
51 PIK3CA R524K 5.05 0.48
51 CD79B Y196S 38.59 0.28
51 CD79B Y196S 41.34 0.29
52 TP53 Y163C 11.04 0.50
53 ATM I352T 7.14 0.50
Full list of members of the ICGC MMML-Seq 
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